About the Project
This programme aims to develop new polymer-drug conjugates for the treatment of a range of cancers. In particular, the incorporation of drug-polymer linkers that are sensitive to enzymes within a range of tumours will be probed to potentially prepare prodrugs for cancer. These polymeric prodrugs should be inactive until they reach the enzyme required for drug release, and since the enzymes will be specific to tumours, selective delivery should result. This approach will present an important advantage compared to traditional polymer anticancer drug conjugates. Whilst the selectivity of the latter relies only on the EPR effect, the proposed system will display a double targeting mechanism: the EPR effect followed by specific activation in the tumour tissue.
The project is highly interdisciplinary and involves a collaboration between Med Chem (Prof Osborn) and Pharmaceutics (Greco)
Why not add a message here
Based on your current searches we recommend the following search filters.
Based on your current search criteria we thought you might be interested in these.